Your browser doesn't support javascript.
loading
Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service.
Maher, Eamonn R; Adlard, Julian; Barwell, Julian; Brady, Angela F; Brennan, Paul; Cook, Jackie; Crawford, Gillian S; Dabir, Tabib; Davidson, Rosemarie; Dyer, Rebecca; Harrison, Rachel; Forde, Claire; Halliday, Dorothy; Hanson, Helen; Hay, Eleanor; Higgs, Jenny; Jones, Mari; Lalloo, Fiona; Miedzybrodzka, Zosia; Ong, Kai Ren; Pelz, Frauke; Ruddy, Deborah; Snape, Katie; Whitworth, James; Sandford, Richard N.
Afiliação
  • Maher ER; Department of Medical Genetics, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK. erm1000@medschl.cam.ac.uk.
  • Adlard J; Clinical Genetics Department, Chapel Allerton Hospital, Leeds, LS7 4SA, UK.
  • Barwell J; Department of Clinical Genetics, University Hospitals of Leicester, Leicester, LE1 5WW, UK.
  • Brady AF; North West Thames Regional Genetics Service, London North West University Healthcare NHS Trust, Northwick Park Hospital, Leicester, HA1 3UJ, UK.
  • Brennan P; Northern Genetics Service, Newcastle Hospitals NHS Foundation Trust, Newcastle, UK.
  • Cook J; Department of Clinical Genetics, Sheffield Children's Hospital NHS Foundation Trust, Sheffield, S10 2TH, UK.
  • Crawford GS; Wessex Clinical Genetics Service, Level G, Princess Anne Hospital, Coxford Road, Southampton, SO16 5YA, UK.
  • Dabir T; Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast, BT9 7AB, UK.
  • Davidson R; Department of Clinical Genetics, Queen Elizabeth University Hospital, Glasgow, G51 4TF, UK.
  • Dyer R; South East of Scotland Clinical Genetics, Western General Hospital, Edinburgh, EH4 2XU, UK.
  • Harrison R; Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Nottingham, NH5 1PB, UK.
  • Forde C; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • Halliday D; Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7HE, UK.
  • Hanson H; Department of Clinical Genetics, St George's University Hospitals NHS Foundation Trust, London, UK.
  • Hay E; Department of Clinical Genetics, Great Ormond Street Hospital, London, WC1N 3JH, UK.
  • Higgs J; Liverpool Centre for Genomic Medicine, Liverpool Women's Hospital, Liverpool, L8 7SS, UK.
  • Jones M; Northern Genetics Service, Newcastle Hospitals NHS Foundation Trust, Newcastle, UK.
  • Lalloo F; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • Miedzybrodzka Z; Medical Genetics Group, University of Aberdeen, Aberdeen, UK.
  • Ong KR; Clinical Genetics Department, Birmingham Women's and Children's NHS Trust, Birmingham, B15 2TG, UK.
  • Pelz F; All Wales Medical Genomics Service, Cardiff and Vale University Health Board, Cardiff, CF14 4XW, UK.
  • Ruddy D; Department of Clinical Genetics, Guys and St Thomas' Hospital, London, SE1 9RTX, UK.
  • Snape K; Department of Clinical Genetics, St George's University Hospitals NHS Foundation Trust, London, UK.
  • Whitworth J; Department of Medical Genetics, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
  • Sandford RN; Clinical Genetics Department, Birmingham Women's and Children's NHS Trust, Birmingham, B15 2TG, UK.
Br J Cancer ; 126(9): 1339-1345, 2022 05.
Article em En | MEDLINE | ID: mdl-35184155
ABSTRACT

BACKGROUND:

Von Hippel-Lindau (VHL) disease is an inherited tumour predisposition syndrome and a paradigm for the importance of early diagnosis and surveillance. However, there is limited information on the "real world" management of VHL disease.

METHODS:

A national audit of VHL disease in the United Kingdom.

RESULTS:

VHL disease was managed mostly via specialist clinics coordinated through regional clinical genetics services (but frequently involving additional specialties). Over the study period, 19 genetic centres saw 842 individuals (393 males, 449 females) with a clinical and/or molecular diagnosis of VHL disease and 74 individuals (35 male, 39 female) with a prior risk of 50% (affected parent). All centres offered retinal, central nervous system and abdominal surveillance to affected individuals and at-risk relatives though surveillance details differed between centres (but complied with international recommendations). Renal lesions detected on the first surveillance scan were, on average, larger than those detected during subsequent scans and the larger the diameter at detection the greater the likelihood of early intervention.

CONCLUSIONS:

In a state-funded health care system individuals with a rare inherited cancer predisposition syndrome are generally able to access appropriate surveillance and patient management is improved compared to historical data. The "real world" data from this study will inform the future development of VHL management protocols.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de von Hippel-Lindau / Neoplasias Tipo de estudo: Evaluation_studies / Guideline / Screening_studies Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Br J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de von Hippel-Lindau / Neoplasias Tipo de estudo: Evaluation_studies / Guideline / Screening_studies Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Br J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido